RxDoctor Payments Data

Rangan Murali, MD

Gastroenterology · Joplin, MONPI 1164687224

Payments from drug & device makers

$1,247in general payments, 2019–2025

Across 58 payments — averaging $21.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$401
  • Sanofi$216
  • Pfizer$99
  • Bristol Myers Squibb$94
  • Boston Scientific$86
  • Takeda Pharmaceuticals U.S.A., Inc.$79
  • plus $273 from 11 others

What the payments were for

  • Food & beverage$1,247100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,247 in reported general payments places this provider in the 45th percentile of 374 gastroenterology providers in Missouri.

See all gastroenterology providers in Missouri

Medicare billing

Part B allowed, 2024
$110,869
Medicare patients
436
Services billed
837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab19$138,297
OcalivaObeticholic Acid11$106,108
LinzessLinaclotide53$31,665
Mesalamine13$7,455
SutabSod Sulf/Pot Chloride/Mag Sulf43$7,081
ClenpiqSod Picosulf/Mag Ox/Citric Ac35$6,164
Mesalamine ErMesalamine13$4,587
Sucralfate105$3,984
Ursodiol37$3,093
Colestipol Hcl65$2,742
Budesonide DrBudesonide16$1,894
Omeprazole203$1,832
Pantoprazole Sodium169$1,659
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl121$1,636
Dicyclomine Hcl86$1,383

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$401$31,66553 claims
Braintree Laboratories, Inc.Sutab$12$7,08143 claims
Ferring Pharmaceuticals Inc.Clenpiq$26$6,16435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 374 gastroenterology providers in Missouri.

Other gastroenterology in Joplin

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →